Status not kept up to date
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
NCT03784040 · National University Hospital, Singapore · Updated 8 April 2019
- What is being tested
- OTSGC-A24; Nivolumab; Ipilimumab
- For
- Gastric Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 21 years to 99 years. About 40 people. The full rules are on the registry page.
- Where
- Singapore
- When
- Starts or started 21 Feb 2019, ends 1 March 2024. Registered 21 Dec 2018.
- Results
- None posted yet.
In the researchers' words
The primary hypothesis is that cancer vaccine can convert non-immunogenic gastric cancer into immunogenic phenotype susceptible to PD1 inhibition. This would lead to an improved radiological response rate and favorable immune contexture for immune checkpoint blockade
Sites
- National University HospitalSingapore, Singapore